Previous 10 | Next 10 |
— Anesthesia-driven regional approaches drive record EXPAREL sales of $507 million in 2021 — — Full-year GAAP net income of $42 million and adjusted EBITDA of $204 million — — More than 10 million patients have received EXPAREL since launch &...
Pacira BioSciences (NASDAQ:PCRX) is scheduled to announce Q4 earnings results on Thursday, February 24th, before market open. The consensus EPS Estimate is $0.83 (-4.6% Y/Y) and the consensus Revenue Estimate is $157.42M (+20.2% Y/Y). Over the last 2 years, PCRX has beaten EPS estimates 88% o...
TAMPA, Fla., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2021 financial results before the open of the U.S. markets on Thursday, February 24, 2022. Following the release, the comp...
John Paulson's fund, Paulson & Co., opened new positions in Cerner (NASDAQ:CERN) (474K shares) and KraneShares CSI China Internet ETF (NYSEARCA:KWEB) (500K shares) and closed stakes in Pretium Resources (NYSE:PVG) and Viatris (NASDAQ:VTRS) during Q4 2021, according to its latest 13F filin...
Pacira BioSciences (NASDAQ:PCRX) has reported preliminary unaudited net product sales for EXPAREL® and iovera° for the month of January 2022. EXPAREL net product sales were $36.3M, compared with $34.9M Y/Y with average daily sales for the month were 104% of January 2021. ...
TAMPA, Fla., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited net product sales for EXPAREL ® (bupivacaine liposome ...
The second part to my series on the Biotechnology industry will be finding the necessary skills to research companies. The concepts are simple, but the information is sometimes difficult to find, and so I provide some examples. The five companies I analyze are just examples, and u...
TAMPA, Fla., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today reported preliminary unaudited total revenue of $540.7 to $541.7 million for 2021, compared wi...
TAMPA, Fla., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will present at the 40 th Annual J.P. Morgan Healthcare Conference at 3:00 PM ET on Monday, January 10, 2022. Live audio of the virtual event can be accessed by visiting th...
The company reports an EPS beat of $0.72 in the third quarter. We look into how management has been employing its capital. We like the results as well as the underlying trend. A bullish move through a breakout above the bullish triangle (below) could be on the cards here short...
News, Short Squeeze, Breakout and More Instantly...
Pacira BioSciences Inc. Company Name:
PCRX Stock Symbol:
NASDAQ Market:
Pacira BioSciences Inc. Website:
TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its second quarter financial results after the close of the U.S. markets on Tuesday July 30, 2024. Following the release, the company will host a live conference call and webc...
-- Proposed Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment System Rule extends separate payment from ambulatory surgical centers to include the hospital outpatient environment – -- Rule implements the NOPAIN Act, signed into law as part of the Cons...
A look at the top 10 most actives in the United States Ocean Power Technologies Inc. (OPTT) rose 86.1% to $0.514 on volume of 587,366,807 shares NVIDIA Corporation (NVDA) fell 1.3% to $122.67 on volume of 214,038,378 shares Tesla Inc. (TSLA) rose 10.2% to $231.26 on volume of 201,850,947 ...